Overview

* Nektar Q3 2025 revenue falls to $11.8 mln from $24.1 mln due to facility sale

* Net loss for Q3 2025 was $35.5 mln

* Operating costs decreased due to facility sale and lower R&D expenses

Outlook

* Nektar expects cash to support operations into Q2 2027

Result Drivers

* REVENUE DECLINE - Revenue decreased due to the sale of the Huntsville manufacturing facility, ending product sales

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $11.79

Product mln

Sales

Q3 EPS -$1.87

Q3 Net -$35.52

Income mln

Q3 -$31.67

Income mln

From

Operatio

ns

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Nektar Therapeutics ( NKTR ) is $100.00, about 45.7% above its November 5 closing price of $54.26

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)